Computational identification of potential multi-drug combinations for reduction of microglial inflammation in Alzheimer disease
Open Access
- 5 June 2015
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 6, 116
Abstract
Like other neurodegenerative diseases, Alzheimer Disease (AD) has a prominent inflammatory component mediated by brain microglia. Reducing microglial inflammation could potentially halt or at least slow the neurodegenerative process. A major challenge in the development of treatments targeting brain inflammation is the sheer complexity of the molecular mechanisms that determine whether microglia become inflammatory or take on a more neuroprotective phenotype. The process is highly multifactorial, raising the possibility that a multi-target/multi-drug strategy could be more effective than conventional monotherapy. This study takes a computational approach in finding combinations of approved drugs that are potentially more effective than single drugs in reducing microglial inflammation in AD. This novel approach exploits the distinct advantages of two different computer programming languages, one imperative and the other declarative. Existing programs written in both languages implement the same model of microglial behavior, and the input/output relationships of both programs agree with each other and with data on microglia over an extensive test battery. Here the imperative program is used efficiently to screen the model for the most efficacious combinations of 10 drugs, while the declarative program is used to analyze in detail the mechanisms of action of the most efficacious combinations. Of the 1024 possible drug combinations, the simulated screen identifies only 7 that are able to move simulated microglia at least 50% of the way from a neurotoxic to a neuroprotective phenotype. Subsequent analysis shows that of the 7 most efficacious combinations, 2 stand out as superior both in strength and reliability. The model offers many experimentally testable and therapeutically relevant predictions concerning effective drug combinations and their mechanisms of action.Keywords
This publication has 60 references indexed in Scilit:
- Microglial aging in the healthy CNS: phenotypes, drivers, and rejuvenationFrontiers in Cellular Neuroscience, 2013
- (+)-Naloxone, an Opioid-Inactive Toll-Like Receptor 4 Signaling Inhibitor, Reverses Multiple Models of Chronic Neuropathic Pain in RatsThe Journal of Pain, 2012
- Novel Computational Approaches to Polypharmacology as a Means to Define Responses to Individual DrugsAnnual Review of Pharmacology and Toxicology, 2012
- CX3CR1 Deficiency Alters Microglial Activation and Reduces Beta-Amyloid Deposition in Two Alzheimer's Disease Mouse ModelsThe American Journal of Pathology, 2010
- CD14 and Toll-Like Receptors 2 and 4 Are Required for Fibrillar Aβ-Stimulated Microglial ActivationThe Journal of Neuroscience, 2009
- Synergistic drug combinations tend to improve therapeutically relevant selectivityNature Biotechnology, 2009
- Toll‐like receptor 4 mediates cross‐talk between peroxisome proliferator‐activated receptor γ and nuclear factor‐κB in macrophagesImmunology, 2008
- Non‐stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll‐like receptor 4 (TLR4)European Journal of Neuroscience, 2008
- Activation of nicotinic acetylcholine receptor prevents the production of reactive oxygen species in fibrillar β amyloid peptide (1-42)-stimulated microgliaExperimental & Molecular Medicine, 2008
- Multicomponent therapeutics for networked systemsNature Reviews Drug Discovery, 2005